Biocytogen's IDE034 ADC Receives FDA IND Clearance for Phase 1 Clinical Trial

Biocytogen Pharmaceuticals' partner IDEAYA Biosciences has received FDA clearance for a Phase 1 clinical trial of IDE034, a B7H3/PTK7 bispecific antibody-drug conjugate. IDE034 is a potential first-in-class treatment for solid tumors, including lung, colorectal, and head and neck cancers. The drug has shown strong anti-tumor activity in preclinical studies and IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161.